Lyophilization USA Conference 2018

SMi Group15 - 16 November 2018, New Jersey, USA.
16% of the top 100 pharmaceutical drugs and 35% of biologic drugs are lyophilized. With more than 30% of the FDA-approved parenterals lyophilized and soon more than half injectable drugs to require lyophilization there is ample room for standardization and expansion of the lyophilization process in pharmaceuticals.

The 4th Annual Lyophilization USA conference will be analysing technological advantages, regulatory challenges and unmet needs within lyophilization.

Day 1 of the Conference (November 15) will be covering Novel Techniques and Advances, Regulatory Challenges and Analytical Processes; Continuous monitoring of sublimation rate for individual containers & Reconstitution challenges of lyophilized highly concentrated protein products; Freeze dryer characterization and application to drug product development and scale up; Formulation and excipient selection for lyo product development of vaccines

Day 2 of the Conference (November 16) will be focusing on challenges that process of lyophilization brings to pharmaceutical and biotechnology companies; Oncobiologics on Freezing of biologics formulations - impact on stability; Panel Discussion on Process modelling and simulation; and also looking into alternatives to conventional methods with the Keynote Address on vacuum-foam drying and key action points on future directions in lyophilization

Featured Speakers

  • Alex Langford - Pfizer
  • Colin Campbell - Elusys Therapeutics
  • Dena Flamm - Optima Machinery Corporation
  • Fabrice Schlegel - Amgen
  • Hiten Gutka - Oncobiologics
  • Morrisa Jones - Merck
  • Alina Alexeenko - Purdue University
  • Rui Fang - Merck Research Laboratories
  • Sushma Kommareddy - Takeda
  • Timothy McCoy - Sanofi

Enhance your knowledge on controlled nucleation, available PAT's and the future of flexible PAT processes, and alternative freeze dryer technologies including spray drying, spin freeze-drying and microwave drying at the Workshop A on November 14 hosted by Alexander Tambovzev and Dena Flamm of Optima Pharma

Are you new to the area of freeze-drying/lyophilization? Sign up to attend the Workshop B on November 14 hosted by Robin Bogner, University of Connecticut and gain an understanding of the essential aspects of freeze-drying.

Further details at http://www.lyophilization-usa.com/wpnWL

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Most Popular Now

Amgen and the Amgen Foundation commit up to $12.5 …

Amgen (NASDAQ:AMGN) and the Amgen Foundation announced an initial commitment of up to $12.5 million to support U.S. and global relief efforts to address critical needs in...

Novartis and life sciences companies commit expert…

Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics...

AstraZeneca to donate 9 million face masks to supp…

AstraZeneca is donating nine million face masks to support healthcare workers around the world as they respond to the COVID-19 (novel coronavirus) global pandemic. AstraZ...

Roche response to COVID-19 pandemic

Roche Group (SIX: RO, ROG; OTCQX: RHHBY), provided an update on the various actions the company is taking to address the COVID-19 pandemic. On March 19, 2020, Roche co...

Singapore modelling study estimates impact of phys…

A new modelling study conducted in a simulated Singapore setting has estimated that a combined approach of physical distancing [2] interventions, comprising quarantine (f...

CAR macrophages go beyond T cells to fight solid t…

Chimeric antigen receptor (CAR) T cell therapy has been a game-changer for blood cancers but has faced challenges in targeting solid tumors. Now researchers from the Pere...

FDA approves first plasma therapy for Houston Meth…

Houston Methodist received FDA approval Saturday to become the first academic medical center in the nation to transfuse donated plasma from a recovered COVID-19 patient i...

Consignment of 30 million hydroxychloroquine table…

Novartis announced that Sandoz, its generics and biosimilars division, has started to ship a consignment of 30 million doses of hydroxychloroquine tablets to the US Depar...

Experimental AI tool predicts which COVID-19 patie…

An artificial intelligence tool accurately predicted which patients newly infected with the COVID-19 virus would go on to develop severe respiratory disease, a new study ...

Vivli to launch a portal for sharing data from COV…

In a visible sign of data sharing leadership, Vivli, the Center for Clinical Research Data has committed to serving the open science community through the launch of a COV...

Roche initiates Phase III clinical trial of Actemr…

Roche (SIX: RO, ROG; OTCQX: RHHBY) is working with the Food & Drug Administration (FDA) to initiate a randomised, double-blind, placebo-controlled Phase III clinical tria...

Novartis commits to donate up to 130 million doses…

Novartis announced its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response. Hydroxychloroquine and...